Ivy Riaնo, Medical Oncologist at Dartmouth Hitchcock Medical Center and Clinics and Assistant Professor at Geisel School of Medicine at Dartmouth, shared a post on X:
“In our editorial, we take a closer look at the EVOKE-02 trial and what its findings could mean for clinical practice.
Greater efficacy in tumors wit high PD-L1 expression Lack of correlation btw Trop-2 expression and efficacy.”
Title: Advancing Frontline Therapy in Metastatic NSCLC: Lessons From EVOKE-02 on Antibody-Drug Conjugates-Immunotherapy Combination
Authors: Ivy Riano, Konstantin Dragnev
Read the Full Article.
Other articles featuring NSCLC on OncoDaily.